This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MAP2K2 / Dual specificity mitogen-activated protein kinase kinase 2 · IHC design guide
Design Immunohistochemistry for MAP2K2
Plan MAP2K2 paraffin IHC around cytoplasmic staining, with high signal reported in colon glandular cells (HPA tissue IHC). In a paraffin-section example, catalog antibody A00996-2 was applied at 2 μg/mL overnight at 4°C (datasheet: A00996-2).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MAP2K2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | General cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining in glandular and hematopoietic cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A00996-2) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Heart muscle+2 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Bone marrow endogenous peroxidase can mimic DAB signal (HPA tissue IHC; standard IHC practice) | |
| Regulation | Expression regulation unreported (UniProt) | |
| Isoform / epitope | No isoforms or cleavage annotated to alter the epitope map (UniProt) |
Section 1
Recommended MAP2K2 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by four published MAP2K2 IHC protocols covering head and neck, pancreatic, breast, and prostate tumors (PMC10741104; PMC10563513; PMC10342177; PMC10126012).
| Sample | Paraffin-embedded human rectal cancer tissue; fixative not specified (datasheet A00996-2) |
| Fixation | Image fixative and duration unreported (datasheet A00996-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A00996-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A00996-2) |
| Primary antibody | Rabbit anti-MAP2K2, 2-5μg/ml (datasheet A00996-2) |
| Primary incubation | Overnight at 4 °C (datasheet A00996-2) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A00996-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MAP2K2-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet A00996-2); use each published retrieval condition when following that article’s protocol.
Section 2
What Is the Expected MAP2K2 Staining Pattern?
In paraffin-section IHC, expect mainly cytoplasmic MAP2K2 staining, particularly in glandular cells of the colon, appendix and duodenum, and in cerebellar Purkinje cells (HPA tissue IHC: High; general cytoplasmic expression). Membrane association may occur through KSR1 interaction, although MAP2K2 has no transmembrane segment (UniProt P36507: subcellular location and topology). HPA rates the tissue pattern Supported, with medium consistency between staining and RNA expression (HPA tissue IHC: reliability).
| Cytoplasmic staining in glandular epithelium or Purkinje cells. | This fits the reported compartment and cell distribution (HPA tissue IHC: general cytoplasmic expression; High in glandular and Purkinje cells). Judge staining within the named cell population rather than treating every cell in a positive tissue as equally positive (HPA tissue IHC: cell-specific levels). |
| Predominantly nuclear staining, with little cytoplasmic signal. | A nuclear-only pattern conflicts with the reported cytoplasmic IHC profile and cytosolic IF location (HPA tissue IHC: profile; HPA subcellular: Cytosol). Investigate nonspecific primary binding, detection background and compartment identification before assigning that signal to MAP2K2 (general IHC practice). |
| Strong staining in cardiomyocytes, skeletal myocytes or smooth muscle cells. | HPA reports MAP2K2 as Not detected in these respective cell populations (HPA tissue IHC: heart, skeletal muscle and smooth muscle). Unexpected signal warrants checks for cross-reactivity or endogenous detection activity; it does not, by itself, establish either cause (general IHC practice). |
| Uniform haze across cells, stroma and tissue-free areas. | A diffuse field obscures the cell and compartment pattern needed to interpret MAP2K2 (HPA tissue IHC: cell-specific cytoplasmic profile). Compare a section processed without primary antibody and review blocking, washes and detection chemistry for background (general IHC practice). |
| No staining in a section expected to contain HPA-high cells. | First confirm that the relevant cells are present: HPA names glandular cells in the colon, appendix and duodenum, and Purkinje cells in the cerebellum (HPA tissue IHC: High). If present, review antibody suitability and the IHC workflow before interpreting the absence as biological (general IHC practice). |
💡Expected MAP2K2 appearanceCall a result positive when identifiable HPA-high glandular or Purkinje cells show chiefly cytoplasmic staining (HPA tissue IHC: High; general cytoplasmic expression); nuclear-only colour or broad cell-independent haze is suspect (HPA subcellular: Cytosol; general IHC practice).
| Tissue and cell selection | HPA reports High staining in several glandular populations, hematopoietic cells and Purkinje cells, but Not detected staining in the listed muscle cell populations (HPA tissue IHC: cell levels). Use the specified cells when comparing sections; low tissue specificity of RNA does not make all cell types equivalent IHC controls (HPA tissue IHC: RNA specificity and staining). |
| Compartment and membrane association | Cytoplasm is the reported IHC pattern, while UniProt lists cytoplasm and membrane and says membrane localization is probably regulated by KSR1 interaction (HPA tissue IHC: profile; UniProt P36507: subcellular location). With no transmembrane segment, a strict cell-surface outline is not the default expected pattern (UniProt P36507: topology). |
| Strength of reference evidence | HPA calls tissue IHC Supported and describes medium consistency with RNA data; its 2 listed antibodies each have Supported IHC status (HPA tissue IHC: reliability; HPA antibodies: HPA051993 and CAB003835). These observations guide pattern checks but do not establish that every sample or staining run must have the same intensity (general IHC practice). |
| IF/ICC Q&A: where should MAP2K2 appear? | Mainly in the cytosol; HPA additionally reports signal in the sperm mid piece, principal piece and end piece (HPA subcellular: enhanced cytosol; approved additional locations). This localization answers the IF/ICC interpretation question and supplies no IF/ICC protocol conditions (HPA subcellular: localization record). |
| Fixation and retrieval evidence | Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation. |
| Situation | Likely cause | Next action |
|---|---|---|
| Known-positive glandular cells show no chromogenic signal. | The expected cells may be absent from the section, or staining and detection may have failed (HPA tissue IHC: High in specified glandular cells; general IHC practice). | Verify cell identity on the counterstain, then review IHC validation, retrieval, primary incubation and detection with a positive control section (general IHC practice). |
| Colour appears equally in negative-control and test sections. | Primary-independent background, including endogenous enzyme activity when enzyme detection is used, is possible (general IHC practice). | Compare a no-primary control, check the detection reagent and apply the appropriate endogenous-activity block for that detection system (general IHC practice). |
| Strong nuclear colour dominates a stained tissue. | This conflicts with reported cytoplasmic IHC and cytosolic IF localization (HPA tissue IHC: profile; HPA subcellular: Cytosol). | Check nuclear boundaries with the counterstain, compare the no-primary control and reassess antibody specificity before scoring MAP2K2 (general IHC practice). |
| Muscle cells stain strongly despite a clean negative control. | HPA reports Not detected staining in cardiomyocytes, skeletal myocytes and smooth muscle cells; the discrepancy needs investigation (HPA tissue IHC: muscle entries). | Confirm cell identity and compare staining with an HPA-high cell population; evaluate primary-antibody specificity if the discrepancy persists (general IHC practice). |
| Signal spreads through stroma and obscures cell borders. | Diffuse background can prevent assessment of the reported cell-specific cytoplasmic pattern (HPA tissue IHC: profile; general IHC practice). | Inspect a no-primary section and review blocking, wash steps, antibody concentration and chromogen development as general IHC practice. |
| A faint membrane outline appears alongside cytoplasmic staining. | Membrane association is plausible through KSR1, but MAP2K2 lacks a transmembrane segment (UniProt P36507: subcellular location and topology). | Score the predominant cytoplasmic pattern and compare controls before treating the outline as specific membrane localization (HPA tissue IHC: profile; general IHC practice). |
Experiment evidence
IHC & IF images showing MAP2K2 staining
A00996-2 · IHCIHC analysis of MEK2/MAP2K2 using anti-MEK2/MAP2K2 antibody (A00996-2). MEK2/MAP2K2 was detected in paraffin-embedded section of human recta
A00996-2 · IHCIHC analysis of MEK2/MAP2K2 using anti-MEK2/MAP2K2 antibody (A00996-2). MEK2/MAP2K2 was detected in paraffin-embedded section of rat brain t
A00996-2 · IFIF analysis of MEK2/MAP2K2 using anti-MEK2/MAP2K2 antibody (A00996-2). MEK2/MAP2K2 was detected in immunocytochemical section of U20S cells.
M00996 · IHCIHC analysis of MAP2K2 using anti-MAP2K2 antibody (M00996). MAP2K2 was detected in a paraffin-embedded section of human stomach cancer tissu
M00996-3 · IHCIHC analysis of MEK2/MAP2K2 using anti-MEK2/MAP2K2 antibody (M00996-3). MEK2/MAP2K2 was detected in paraffin-embedded section of human renal
M00996-3 · IFIF analysis of MEK2/MAP2K2 using anti-MEK2/MAP2K2 antibody (M00996-3). MEK2/MAP2K2 was detected in immunocytochemical section of MCF-7 cells
M00996-2 · IFIF analysis of MEK2/MAP2K2 using anti-MEK2/MAP2K2 antibody (M00996-2). MEK2/MAP2K2 was detected in immunocytochemical section of MCF-7 cells
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000126934-MAP2K2/tissue/cerebral+cortex#imid_1315748
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000126934-MAP2K2/tissue/colon#imid_1315674
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000126934-MAP2K2/tissue/liver#imid_1315667
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000126934-MAP2K2/tissue/kidney#imid_1315676
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB003835; green = MAP2K2, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB003835; green = MAP2K2, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MAP2K2 IHC & IF
🧪Run colon first: glandular cells should stain strongly (HPA: High in colon glandular cells); use skeletal muscle as the negative tissue, where myocytes are not detected (HPA: Not detected in skeletal muscle myocytes). On the colon slide, treat cells outside the glands as internal negatives only if their MAP2K2 status is independently established; the supplied HPA row does not establish their staining level (HPA: colon glandular cells only).
Positive control tissue: Appendix (Glandular cells, HPA High)
Negative control tissue: Heart muscle (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MAP2K2 in A-431, U-251MG, U2OS, MCF-7, Sperm, NIH 3T3, with annotated localisation: Cytosol (enhanced) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) slide, matched nonimmune rabbit IgG isotype control, and a MAP2K2 knockout specimen or validated peptide-block control (catalog antibody caption: rabbit primary). For the biotin-based DAB detection shown, control endogenous peroxidase and biotin in colon sections (catalog antibody caption: biotinylated secondary, SABC and DAB).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported, and the selected-SKU paraffin-section caption does not state the fixative (A00996-2 tissue-IHC caption: fixative not stated). The reported IHC conditions use heat retrieval in EDTA at pH 8.0; this documents a working condition, not that retrieval is required (A00996-2 tissue-IHC caption). Frozen-section performance and whether IF is easier are unreported; ICC-IF images support cytosolic localisation, while colon sections warrant attention to endogenous peroxidase and biotin signal with the reported detection method (HPA subcellular: Cytosol enhanced; A00996-2 tissue-IHC caption: SABC and DAB).
HPA tissue IHC evidence for MAP2K2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Cerebellum | Purkinje cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
Section 3
Advanced MAP2K2 IHC Tips
Troubleshoot MAP2K2 staining in paraffin sections by checking retrieval, cell compartment, controls, and scoring before interpreting differences in signal.
What retrieval should I try first when MAP2K2 staining is weak in paraffin sections?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A00996-2). The catalog antibody detected MAP2K2 in a paraffin-embedded human rectal cancer section after this retrieval, followed by 2 µg/mL primary antibody overnight at 4°C (datasheet A00996-2). If staining is weak, check heating consistency, section adhesion, and whether the retrieval solution maintained its pH before changing the antibody concentration (standard IHC practice). Run a known positive section alongside the test section, and assess whether signal remains predominantly cytoplasmic (HPA: general cytoplasmic expression; standard IHC practice).
How should I troubleshoot variable MAP2K2 staining after fixation?
The supplied catalog caption identifies paraffin embedding but does not state a fixative, so MAP2K2-specific sensitivity to fixation is unknown (datasheet A00996-2). Record the fixative, fixation duration, tissue thickness, and processing history for each section before comparing staining intensity (standard IHC practice). Apply the same EDTA pH 8.0 retrieval and 2 µg/mL primary incubation across a comparison set (datasheet A00996-2; standard IHC practice). If signal varies, compare sections from matched processing runs with a positive control and inspect morphology; neither HPA staining patterns nor MAP2K2 topology establishes a fixation effect (standard IHC practice; UniProt P36507 topology).
Should MAP2K2 staining appear at the membrane or mainly in the cytoplasm?
Expect predominantly cytoplasmic staining in chromogenic IHC, consistent with the tissue profile of general cytoplasmic expression (HPA: tissue IHC profile). MAP2K2 is annotated in the cytoplasm and at membranes, with membrane localisation probably regulated by interaction with KSR1 (UniProt P36507 subcellular location). It has no transmembrane segment, so a continuous, exclusive membrane rim warrants closer scrutiny (UniProt P36507 topology; standard IHC interpretation). Compare the suspect pattern with neighbouring cells, the positive control, and a secondary-only control before calling it specific (standard IHC practice). Record cytoplasmic and membrane-associated staining separately when both are visible (standard IHC practice).
Could isoforms or phosphorylation explain a change in MAP2K2 IHC staining?
The supplied record lists 0 isoforms and one chain spanning residues 1–400, so an isoform-specific explanation is unsupported here (UniProt P36507 processing and isoforms). MAP2K2 has a protein kinase domain at residues 72–369 and annotated modified residues, including RAF-associated phosphorylation at residue 222 (UniProt P36507 domains and modified residues). The catalog caption does not identify the antibody epitope or establish sensitivity to those modifications (datasheet A00996-2). Check the antibody’s documented epitope and validation data before attributing a changed chromogenic signal to phosphorylation (standard IHC practice). Hold retrieval and detection conditions constant while comparing sections (standard IHC practice).
How can I use IF to investigate an uncertain MAP2K2 IHC pattern?
Use IF as a separate follow-up to a chromogenic IHC finding; the supplied catalog caption documents paraffin-section IHC, not validation of this antibody for IF (datasheet A00996-2). Multiplex MAP2K2 with a validated marker for the cell type under examination, then compare cell identity and cytosolic signal across channels (HPA: mainly cytosolic; standard IF practice). Choose fluorophores after examining unstained tissue autofluorescence, and include single-label controls to assess spectral overlap (standard IF practice). Because MAP2K2 lacks a transmembrane segment and is mainly cytosolic, optimise permeabilisation for intracellular access while preserving morphology (UniProt P36507 topology; HPA: cytosol; standard IF practice).
What should I check when MAP2K2 DAB staining looks diffuse?
The catalog IHC example used 10% goat serum blocking, 2 µg/mL primary antibody, a biotinylated secondary, and DAB development (datasheet A00996-2). First compare a primary-omission control with the stained section to identify signal arising from detection reagents or tissue components (standard IHC practice). Check endogenous peroxidase blocking and, for the biotin-based detection used in the example, assess endogenous biotin interference (datasheet A00996-2; standard IHC practice). If background persists, titrate the primary and review washing and DAB development while keeping the EDTA pH 8.0 retrieval consistent (datasheet A00996-2; standard IHC practice). Score only cellular staining with interpretable morphology (standard IHC practice).
How should I quantify MAP2K2 staining across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and region of interest before scoring, because HPA reports high staining in colon glandular cells and no detected staining in heart muscle cardiomyocytes (HPA: tissue IHC). For cellular staining, record the percentage of positive cells and intensity, or calculate an H-score from intensity categories 0–3 (standard IHC practice). If counting positive cells, report density per mm² of viable tissue and normalise comparisons to the same cell compartment or annotated cell population (standard IHC practice). Keep section thickness, retrieval, exposure to DAB, and threshold rules consistent across the comparison set (standard IHC practice). Report cytoplasmic and membrane-associated staining separately if both occur (UniProt P36507 subcellular location; standard IHC practice).
How can I distinguish genuine MAP2K2 staining from artefact?
A plausible positive pattern is cellular and mainly cytoplasmic, consistent with HPA tissue staining and its cytosol localisation data (HPA: tissue IHC and subcellular). Compare staining with expected cell populations: colon glandular cells are reported high, whereas heart muscle cardiomyocytes are reported not detected (HPA: tissue IHC). Treat isolated nuclear staining or a uniform membrane rim cautiously because the supplied localisation evidence favours cytoplasm, with regulated membrane association (UniProt P36507 subcellular location; HPA: tissue IHC). Exclude section edges, necrotic areas, and deposits from scoring, then inspect primary-omission and peroxidase controls for detection artefacts (standard IHC practice). Recheck questionable regions against tissue morphology and a positive control (standard IHC practice).
Boster reagents
Best MAP2K2 / Dual specificity mitogen-activated protein kinase kinase 2 IHC Antibodies
Catalog images document paraffin-section IHC in human tumors and mouse and rat brain, plus IF/ICC in U20S, K562, and MCF-7 cells (catalog image captions).
Real IHC data
Anti-MEK2/MAP2K2 Antibody ®
Cat # A00996-2
Real IHC data
Anti-MEK2 MAP2K2 Rabbit Monoclonal Antibody
Cat # M00996
Real IHC data
Anti-MEK2/MAP2K2 Antibody ® (monoclonal, 2H4)
Cat # M00996-3
Real IF data
Anti-MEK2/MAP2K2 Antibody ® (monoclonal, 2B4)
Cat # M00996-2
A00996-2 has IHC images from human rectal cancer and mouse and rat brain, plus IF/ICC images from U20S and K562 cells (A00996-2 image captions); M00996 has an IHC image from human stomach cancer (M00996 IHC caption). M00996-3 has an IHC image from human renal clear cell carcinoma and an IF/ICC image from MCF-7 cells (M00996-3 image captions); M00996-2 has an IF/ICC image from MCF-7 cells and does not list IHC as an application (M00996-2 image caption; catalog applications).
Which to pick: For paraffin-section IHC, choose A00996-2 for human rectal cancer or mouse and rat brain (2–5 μg/mL; A00996-2 catalog dilution and IHC captions), M00996 for human stomach cancer (1:50; M00996 catalog dilution and IHC caption), or mouse monoclonal M00996-3 for human renal clear cell carcinoma (2 μg/mL in its IHC caption; M00996-3 catalog clone and IHC caption). For IF/ICC, mouse monoclonals M00996-2 and M00996-3 have MCF-7 images, while A00996-2 has U20S and K562 images (catalog clones and IF captions). For cross-species tissue IHC, A00996-2 has human, mouse, and rat paraffin-section images (A00996-2 IHC captions); the fixative is unreported in the paraffin-section captions (catalog IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P36507 (MP2K2_HUMAN, Dual specificity mitogen-activated protein kinase kinase 2).
- Human Protein Atlas. MAP2K2 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. MAP2K2 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the mid piece, principal piece and end piece..
- Human Protein Atlas. MAP2K2 antibody validation summary (2 antibodies).
- The Prognosis Performance of a Neutrophil- and Lymphocyte-Associated Gene Mutation Score in a Head and Neck Cancer Cohort. Biomedicines 2023 — PMC10741104.
- Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell. Frontiers in immunology 2023 — PMC10563513.
- Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer. International journal of molecular sciences 2023 — PMC10342177.
- Post-transcriptional modification of m(6)A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer. Cell death & disease 2023 — PMC10126012.
- PubMed PMID:8388392 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:17116858 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MAP2K2 (Dual specificity mitogen-activated protein kinase kinase 2). Expected localisation General cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A00996-2). Validated IHC antibody: A00996-2 at 2-5μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Glandular cells); negative Heart muscle. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human rectal cancer tissue; fixative not specified (datasheet A00996-2); 2. Fixation: Image fixative and duration unreported (datasheet A00996-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A00996-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A00996-2); 8. Primary antibody: Rabbit anti-MAP2K2, 2-5μg/ml (datasheet A00996-2); 9. Primary incubation: Overnight at 4 °C (datasheet A00996-2). Watch for: Fixation: Keep fixation conditions consistent across sections (standard IHC practice; not target-specific); Caveat: Bone marrow endogenous peroxidase can mimic DAB signal (HPA tissue IHC; standard IHC practice); Isoform / epitope: No isoforms or cleavage annotated to alter the epitope map (UniProt); Regulation: Expression regulation unreported (UniProt). Evidence: UniProt P36507, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the cytosol. In addition localized to the mid…, Datasheet A00996-2, PMC10741104, PMC10563513. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MAP2K2/immunohistochemistry-ihc-guide.